Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits
Wouter Peelaerts, Liza Bergkvist, Sonia George, Michaela Johnson, Lindsay K. Meyerdirk, Emily Ku, Jennifer A. Steiner, Zachary Madaj, Jiyan Ma, Katelyn Becker, K. Peter R. Nilsson, Jerry R. Colca, Patrik Brundin
The paper tests if inhibiting the mitochondrial pyruvate carrier reduces synucleinopathy in PD models but finds no effect on Syn aggregation or neurodegeneration.
bioRxiv · Oct 1, 2020 · PreprintNeuroscience